Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE)
Will COVID-19 vaccines be safe? Will all the COVID-19 candidate vaccines be successful? What are the different phases a vaccine must go through to be approved? This document provides responses to the most frequently asked questions about candidate vaccines and access to COVID-19 vaccination.
As the world waits for a potential COVID-19 vaccine, we delve into how vaccines actually work. What are the different types of vaccine? How do they trigger and train the immune system, and what is the role of herd immunity?
COVAXINTM, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) h...igh containment facility.
The vaccine received DCGI approval for Phase I & II Human Clinical Trials and the trials commenced across India from July, 2020.
After successful completion of the interim analysis from the Phase 1 & 2 clinical trials of COVAXINTM, Bharat Biotech received DCGI approval for Phase 3 clinical trials in 26,000 participants in over 25 centres across India.
more
22 December 2020
The COVID-19 vaccine safety guidance manual has been developed upon recommendation and guidance of GACVS members, as well as by experts incorporating current and available information critical to all stakeholders when COVID-19 vaccines will be introduced.
For ease of use, the man...ual is available in a compiled form and in several separate modules that can be consulted individually. For each module, specific training material is also available to facilitate implementation.
more
This page provides links to key COVID-19 vaccine resource
pages from IAC, CDC, and other partners.
For the most current COVID-19 vaccine information, subscribe to IAC’s weekly e-newsletter, IAC Express.
For information about routine and catch-up vaccination during the COVID-19 pandemic, vis...it IAC’s Vaccination and COVID-19 page.
more
The authors review some common myths circulating about the vaccine and clear up confusion with reliable facts.
This guide is intended to support national governments developing their national deployment and vaccination plans (NDVPs) for COVID-19 vaccines by outlining the roles, needs and opportunities for community health workers (CHWs) to contribute. This note builds on and is structured to align with the G...uidance on developing a national deployment and vaccination plan for COVID-19 vaccines. By providing CHW-relevant considerations for the VIRAT Tool, this document aims to support national governments in developing robust NDVPs for introducing COVID-19 vaccine(s) that leverage all the community-based deployment, implementation and monitoring tools at their disposal.
more
انعدام الوصول، والبنية التحتية التالفة، والتحيّز يهددون الحملة
Syria: Covid-19 Vaccine Access Should Be Expanded, Fair (Arabic): Lack of Access, Damaged Infrastructure, Bias Pose Rollout Risk
A free course to help journalists translate the language of vaccine science and the promise of vaccine access into compelling human stories.
Vaccinator's Manual. CONVIDECIA Vaccine
Vaccinator's Manual. MODERNA Vaccine
Interim recommendations for the use of ChAdOx1-S [recombinant] COVID-19 vaccine (AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™ vaccine) - Last updated 30 July 2021
an approach to optimize the global impact of COVID-19 vaccines, based on public health goals, global and national equity, and vaccine access and coverage scenarios, first issued 20 October 2020, updated: 13 November 2020, updated: 16 July 2021, latest update: 21 January 2022
Available in English, F...rench, Spanish
more
L’ensemble du personnel de santé qui participe au déploiement et à la mise en œuvre de la vaccination contre la COVID-19 doit avoir les connaissances et les compétences requises pour garantir une administration sûre et efficace du vaccin contre la COVID-19. Ce cours de formation fournit des ...informations essentielles sur les vaccins contre la COVID-19, à l’aide de courtes vidéos didactiques, de documents explicatifs sur les vaccins, d’aide-mémoire, de sommaires thématiques et de présentations à télécharger.
Please note that further videos and resources concerning other vaccines will be added as they receive emergency use listing (EUL) or prequalification. Available in different languages
more
Rabies is a public health problem in Asia and vaccine affordability is an issue.
There is no reduction in the number of persons seeking post-exposure prophylaxis.
The high cost of cell culture vaccines for intramuscular use is a limiting factor.
Intradermal rabies vaccination offers cost-effectiv...e alternative to intramuscular.
WHO recommended one week intradermal schedule will ensure good patient compliance.
more
Rabies is a zoonotic, vaccine-preventable viral disease that causes damage to the brain and spinal
cord in infected animals and humans. A zoonotic disease is a disease that can be transmitted
between animals and humans. Rabies is nearly 100% fatal once symptoms appear.
WHO strongly recommends discontinuation of the nerve tissue vaccine, and replacement with modern concentrated and purified cell culture derived vaccines (CCDV) and embryonated eggbased rabies vaccines.
These vaccines must comply with WHO criteria for potency and innocuity following satisfactory ass...essment in humans during well-designed field trials
more
The backsliding of immunization coverage during the COVID-19 pandemic, combined with delayed catch-up efforts has resulted in a large and growing immunity gap. There is an urgent need to close this gap, and enable millions of missed children to be vaccinated. The Essential Immunization Recovery Plan... sets out a path to getting immunization back on track, framed by three key approaches – Catch-Up, Restore and Strengthen. This document serves as the joint strategic description of this coordinated effort by WHO, UNICEF, and Gavi, the Vaccine Alliance, along with the Immunization Agenda 2030 (IA2030) Partnership, to support countries to plan and implement intensified efforts to bolster immunization programmes in 2023 and beyond.
more
Introduction Pharmacovigilance (PV) systems to monitor drug and vaccine safety are often inadequate in sub-Saharan
Africa. In Malawi, a PV enhancement initiative was introduced to address major barriers to PV.
Objective The objective of this initiative was to improve reporting of adverse events (A...Es) by strengthening passive safety
surveillance via PV training and mentoring of local PV stakeholders and healthcare providers (HCPs) at their own healthcare
facilities (HCFs).
Methods An 18-month PV training and mentoring programme was implemented in collaboration with national stakeholders,
and in partnership with the Ministry of Health, GSK and PATH. Two-day training was provided to Expanded Programme on
Immunisation coordinators, identified as responsible for AE reporting, and four National Regulatory Authority representa-
tives. Abridged PV training and mentoring were provided regularly to HCPs. Support was given in upgrading the national
PV system. Key performance indicators included the number of AEs reported, transmission of AE forms, completeness of
reports, serious AEs reported and timeliness of recording into VigiFlow.
Results In 18 months, 443 HCPs at 61 HCFs were trained. The number of reported AEs increased from 22 (January 2000 to
October 2016) to 228 (November 2016 to May 2018), enabling Malawi to become a member of the World Health Organization
Programme for International Drug Monitoring. Most (98%) AE report forms contained mandatory information on reporter,
event, patient and product, but under 1% were transmitted to the national PV office within 48 h.
Conclusion Regular PV training and mentoring of HCPs were effective in enhancing passive safety surveillance in Malawi,
but the transmission of reports to the national PV centre requires further improvement.
more